<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="127786">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01945775</url>
  </required_header>
  <id_info>
    <org_study_id>673-301</org_study_id>
    <secondary_id>U1111-1155-7579</secondary_id>
    <nct_id>NCT01945775</nct_id>
  </id_info>
  <brief_title>A Study Evaluating BMN 673, a PARP Inhibitor, in Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (EMBRACA Study)</brief_title>
  <acronym>EMBRACA</acronym>
  <official_title>A Phase 3, Open-Label, Randomized, Parallel, 2-Arm, Multi-Center Study of BMN 673 Versus Physician's Choice in Germline BRCA Mutation Subjects With Locally Advanced and/or Metastatic Breast Cancer, Who Have Received No More Than 2 Prior Chemotherapy Regimens for Metastatic Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>BioMarin Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Breast Cancer Coalition (NBCC)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Translational Research in Oncology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>US Oncology Research</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Myriad Genetics, Inc.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>BioMarin Pharmaceutical</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this open-label, 2:1 randomized phase III trial is to compare the safety and
      efficacy of BMN 673 versus protocol-specific physician's choice in patients who have locally
      advanced and/or metastatic breast cancer with germline BRCA mutations.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2013</start_date>
  <primary_completion_date type="Anticipated">June 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>Anticipated in about 24-30 months following first patient enrolled</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluate objective response rate (ORR)</measure>
    <time_frame>Anticipated in about 24-30 months following first patient enrolled</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate overall survival (OS)</measure>
    <time_frame>Anticipated in about 24-30 months following first patient enrolled</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <other_outcome>
    <measure>Duration of response (DOR) for objective responders</measure>
    <time_frame>Anticipated in about 24-30 months following first patient enrolled</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>Health-related quality of life</measure>
    <time_frame>Anticipated in about 24-30 months following first patient enrolled</time_frame>
    <safety_issue>No</safety_issue>
    <description>2 Validated questionnaires to assess general quality of life and deterioration due to breast cancer</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">429</enrollment>
  <condition>Breast Neoplasms</condition>
  <condition>BRCA 1 Gene Mutation</condition>
  <condition>BRCA 2 Gene Mutation</condition>
  <arm_group>
    <arm_group_label>BMN 673</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patient will be randomized 2:1 to receive BMN 673 oral capsules (1.0 mg) once daily for 21 continuous days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Physician's-Choice</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Capecitabine, Eribulin, Gemcitabine or Vinorelbine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMN 673</intervention_name>
    <description>Until progression or unacceptable toxicity develops</description>
    <arm_group_label>BMN 673</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Physician's-Choice</intervention_name>
    <description>Capecitabine, Eribulin, Gemcitabine or Vinorelbine</description>
    <arm_group_label>Physician's-Choice</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically or cytologically confirmed carcinoma of the breast

          -  Locally advanced and/or metastatic disease appropriate for systemic single cytotoxic
             chemotherapy

          -  Deleterious or pathogenic germline BRCA1 or BRCA2 mutation

          -  No more than 2 prior chemotherapy-inclusive regimens for locally advanced and/or
             metastatic disease

          -  Prior treatment with a taxane and/or anthracycline in the adjuvant or metastatic
             setting

          -  ECOG performance status ≤ 1

          -  Have adequate organ function

        Exclusion Criteria:

          -  Prior treatment with a PARP inhibitor

          -  Prior platinum treatment for metastatic disease. Subjects who have received platinum
             in the adjuvant or neoadjuvant setting are eligible

          -  CNS metastasis except adequately treated brain metastasis documented by baseline CT
             or MRI scan that has not progressed since previous scans and that does not require
             corticosteroids for management of CNS symptoms

          -  Prior malignancy except for prior BRCA-associated cancer as long as there is no
             current evidence of the prior cancer, carcinoma in situ of the cervix or non-melanoma
             skin cancer, and a cancer diagnosed and definitively treated ≥5 years prior to study
             enrollment with no subsequent evidence of recurrence

          -  Known to be human HIV positive, active hepatitis C virus, or active hepatitis B virus

          -  Known hypersensitivity of any of the components of BMN 673
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Debra Lounsbury, RN, MS</last_name>
    <email>dlounsbury@bmrn.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Denis Mir, MSc</last_name>
    <email>dmir@bmrn.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Scottsdale Healthcare</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85258</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joyce Schaffer, MSN, RN</last_name>
      <phone>480-323-1339</phone>
      <email>joschaffer@shc.org</email>
    </contact>
    <investigator>
      <last_name>Jasgit C Sachdev, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Arizona Oncology Associates, PC - NAHOA (US Oncology Research)</name>
      <address>
        <city>Sedona</city>
        <state>Arizona</state>
        <zip>86336</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zuzanne Bristow, MPH</last_name>
      <phone>281-863-4673</phone>
      <email>Zuzanne.Bristow@mckesson.com</email>
    </contact>
    <investigator>
      <last_name>Deborah L. Lindquist, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Jude Heritage</name>
      <address>
        <city>Fullerton</city>
        <state>California</state>
        <zip>92835</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>William Lawler, MD</last_name>
      <phone>714-446-5900</phone>
      <email>William.Lawler@stjoe.org</email>
    </contact>
    <contact_backup>
      <last_name>Gayle Madden-Mathes</last_name>
      <phone>714-446-5804</phone>
      <email>Gayle.Madden-MAthes@stjoe.org</email>
    </contact_backup>
    <investigator>
      <last_name>William Lawler, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Marin Cancer Care, Inc.</name>
      <address>
        <city>Greenbrae</city>
        <state>California</state>
        <zip>94904</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jaime Chang, BS,CCRP</last_name>
      <phone>415-925-5040</phone>
      <email>jchang@marinspecialtycare.com</email>
    </contact>
    <investigator>
      <last_name>Peter D. Eisenberg, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Southern California Oncology Research Alliance (SCORA) Network</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90017</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lasika Seneviratne, MD</last_name>
      <email>lasikas27@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Ruma Barva</last_name>
      <phone>310-989-7757</phone>
      <email>rbarva@scoranet.org</email>
    </contact_backup>
    <investigator>
      <last_name>Lasika Seneviratne, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cancer Care Associates Medical Group</name>
      <address>
        <city>Redondo Beach</city>
        <state>California</state>
        <zip>90277</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Chan, MD</last_name>
      <phone>310-750-3376</phone>
      <email>cca.rb@verizon.net</email>
    </contact>
    <contact_backup>
      <last_name>Meg Feder</last_name>
      <phone>(310) 750-3376</phone>
      <email>mfender@mednet.ucla.edu</email>
    </contact_backup>
    <investigator>
      <last_name>David Chan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Coastal Integrative Cancer Care</name>
      <address>
        <city>San Luis Obispo</city>
        <state>California</state>
        <zip>93401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brian DiCarlo, MD</last_name>
      <phone>805-543-5577</phone>
      <email>briandicarlo@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Jessica Free</last_name>
      <phone>805-543-5577</phone>
      <email>jfree@ohmacc.com</email>
    </contact_backup>
    <investigator>
      <last_name>Brian DiCarlo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sansum Clinic</name>
      <address>
        <city>Santa Barbara</city>
        <state>California</state>
        <zip>93105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julie Taguchi, MD</last_name>
      <phone>805-898-3602</phone>
      <email>research@ccsb.org</email>
    </contact>
    <contact_backup>
      <last_name>Alexis Donaire</last_name>
      <phone>(805) 898-3602</phone>
      <email>adonaire@ccsb.org</email>
    </contact_backup>
    <investigator>
      <last_name>Julie Taguchi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Central Coast Medical Oncology</name>
      <address>
        <city>Santa Maria</city>
        <state>California</state>
        <zip>93454</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert Dichmann, MD</last_name>
      <phone>805-349-9393</phone>
      <email>robert@ccmo.us</email>
    </contact>
    <contact_backup>
      <last_name>Alison Fernandez</last_name>
      <phone>(805) 346-3461</phone>
      <email>alison.fernandez@dignityhealth.org</email>
    </contact_backup>
    <investigator>
      <last_name>Robert Dichmann, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rocky Mountain Cancer Centers, LLP (US Oncology Research)</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80218</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zuzanne Bristow, MPH</last_name>
      <phone>281-863-4603</phone>
      <email>Zuzanne.Bristow@mckesson.com</email>
    </contact>
    <investigator>
      <last_name>Sami Diab, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cancer Center of Central Connecticut</name>
      <address>
        <city>Southington</city>
        <state>Connecticut</state>
        <zip>06489</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter Byeff, MD</last_name>
      <phone>860-621-9316</phone>
      <email>peter.byeff@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Mark Turney</last_name>
      <email>mjt2716@sbcglobal.net</email>
    </contact_backup>
    <investigator>
      <last_name>Peter Byeff, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UM Sylvester at Deerfield Beach</name>
      <address>
        <city>Deerfield Beach</city>
        <state>Florida</state>
        <zip>33442</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lori Kronish</last_name>
      <phone>954-461-2111</phone>
      <email>LKronish@med.miami.edu</email>
    </contact>
    <contact_backup>
      <last_name>Lesley Thompson</last_name>
      <phone>954-698-3616</phone>
      <email>LThompson2@med.miami.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Reshma Mahtani, DO</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cancer Specialists of North Florida</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32256</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bijoy Telivala, MD</last_name>
      <phone>904-519-2731</phone>
      <email>Bijoy.telivala@csnf.us</email>
    </contact>
    <contact_backup>
      <last_name>Melissa Rammage</last_name>
      <phone>9904) 519-2731</phone>
      <email>Melissa.Rammage@CSNF.US</email>
    </contact_backup>
    <investigator>
      <last_name>Bijoy Telivala, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center Orlandp</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32773</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rebecca Moroose, MD</last_name>
      <phone>321-843-8370</phone>
      <email>Rebecca.Moroose@orlandohealth.com</email>
    </contact>
    <contact_backup>
      <last_name>Georgina Hollenbach</last_name>
      <phone>321-841-1907</phone>
      <email>georgina.hollenbach@orlandohealth.com</email>
    </contact_backup>
    <investigator>
      <last_name>Rebecca Moroose, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Orchard Healthcare Research Inc.</name>
      <address>
        <city>Skokie</city>
        <state>Illinois</state>
        <zip>60077</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ira Oliff, MD</last_name>
      <email>ira.oliff@orchardhr.com</email>
    </contact>
    <contact_backup>
      <last_name>Joy Jardinico</last_name>
      <phone>(224) 534-7580</phone>
      <email>jjardinico@orchardhr.com</email>
    </contact_backup>
    <investigator>
      <last_name>Ira Oliff, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Carle Foundation Hospital DBA Carle Cancer Center (US Oncology Research)</name>
      <address>
        <city>Urbana</city>
        <state>Illinois</state>
        <zip>61801</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zuzanne Bristow, MPH</last_name>
      <phone>281-863-4603</phone>
      <email>Zuzanne.Bristow@mckesson.com</email>
    </contact>
    <investigator>
      <last_name>Maria T. Grosse-Perdekamp, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Indiana University Healt - Melvin and Bren Simon Cancer Center</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lida Mina, MD</last_name>
      <email>lmina@iu.edu</email>
    </contact>
    <contact_backup>
      <last_name>LaTrice Vaughn, RN</last_name>
      <phone>317.278.3730</phone>
      <email>lgvaughn@iupui.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Lida Mina, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Judy Luckhardt</last_name>
      <email>jluck@med.umich.edu</email>
    </contact>
    <investigator>
      <last_name>Norah Lynn Henry, M.D, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cancer &amp; Hematology Centers of Western Michigan</name>
      <address>
        <city>Grand Rapids</city>
        <state>Michigan</state>
        <zip>49506</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeff Trytko</last_name>
      <phone>616-954-5550</phone>
      <phone_ext>2041</phone_ext>
      <email>jtrytko@chcwm.com</email>
    </contact>
    <contact_backup>
      <last_name>Madhuri Kakarala, MD, PhD</last_name>
      <phone>616-954-9800</phone>
      <email>mkakarala@chcwm.com</email>
    </contact_backup>
    <investigator>
      <last_name>Madhuri Kakarala, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Minnesota Oncology Hematology, P.A. (US Oncology Research)</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zuzanne Bristow, MPH</last_name>
      <phone>281-863-4603</phone>
      <email>Zuzanne.Bristow@mckesson.com</email>
    </contact>
    <investigator>
      <last_name>Michaela L. Tsai, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Comprehensive Cancer Centers of Nevada (US Oncology Research)</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89169</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zuzanne Bristow, MPH</last_name>
      <phone>281-863-4603</phone>
      <email>Zuzanne.Bristow@mckesson.com</email>
    </contact>
    <investigator>
      <last_name>Mary Ann Allison, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>New York Oncology Hematology, P.C. (US Oncology Research)</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <zip>12206</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zuzanne Bristow, MPH</last_name>
      <phone>281-863-4603</phone>
      <email>Zuzanne.Bristow@mckesson.com</email>
    </contact>
    <investigator>
      <last_name>Karen L. Tedesco, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northwest Cancer Specialists, P.C. (US Oncology Research)</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97225</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zuzanne Bristow, MPH</last_name>
      <phone>281-863-4603</phone>
      <email>Zuzanne.Bristow@mckesson.com</email>
    </contact>
    <investigator>
      <last_name>Lucy Langer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Eastern Regional Medical Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19124</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sramila Aithal, MD</last_name>
      <phone>215-537-7400</phone>
      <email>sramila.aithal@ctca-hope.com</email>
    </contact>
    <contact_backup>
      <last_name>Michelle Niesley</last_name>
      <phone>215-537-3160</phone>
      <email>michelle.niesley@ctca-hope.com</email>
    </contact_backup>
    <investigator>
      <last_name>Sramila Aithal, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Magee-Women's Hospital of UPMC</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shannon Huggins-Puhalla, MD</last_name>
      <phone>412-641-3494</phone>
      <email>puhallasl@mail.magee.edu</email>
    </contact>
    <contact_backup>
      <last_name>Brenda Steele</last_name>
      <phone>412-641-2261</phone>
      <email>steeleb@upmc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Shannon Puhalla, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Tennessee Medical Center</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37920</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shanna Overbey, BS, RN</last_name>
      <phone>865-305-9773</phone>
      <email>soverbey@utmck.edu</email>
    </contact>
    <investigator>
      <last_name>Timothy J. Panella, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The West Clinic</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38120</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cindy Inman</last_name>
      <email>cinman@westclinic.com</email>
    </contact>
    <investigator>
      <last_name>Lee Schwartzberg, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tennessee Oncology</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Denise Yardley, MD</last_name>
      <phone>615-329-7274</phone>
      <email>dyardley@tnonc.com</email>
    </contact>
    <contact_backup>
      <last_name>Lisa Simons</last_name>
      <phone>615-329-7497</phone>
      <email>lisa.simons@scresearch.net</email>
    </contact_backup>
    <investigator>
      <last_name>Denise Yardley, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Oncology, P.A. (US Oncology Research)</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zuzanne Bristow, MPH</last_name>
      <phone>281-863-4603</phone>
      <email>Zuzanne.Bristow@mckesson.com</email>
    </contact>
    <investigator>
      <last_name>Joanne L. Blum, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Oncology, P.A. (US Oncology Research)</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zuzanne Bristow, MPH</last_name>
      <phone>281-863-4603</phone>
      <email>Zuzanne.Bristow@mckesson.com</email>
    </contact>
    <investigator>
      <last_name>Kristi J. McIntyre, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Oncology, P.A. (US Oncology Research)</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77024</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zuzanne Bristow, MPH</last_name>
      <phone>281-863-4603</phone>
      <email>Zuzanne.Bristow@mckesson.com</email>
    </contact>
    <investigator>
      <last_name>Frankie Ann Holmes, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The University of Texas MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Litton, MD</last_name>
      <phone>713-792-2817</phone>
      <email>jlitton@mdanderson.org</email>
    </contact>
    <contact_backup>
      <last_name>Jie Zhang</last_name>
      <phone>713-563-0735</phone>
      <email>JieZhang@mdanderson.org</email>
    </contact_backup>
    <investigator>
      <last_name>Jennifer Litton, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Millennium Oncology</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77090</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laurent Gressot, MD</last_name>
      <phone>832-330-5090</phone>
      <email>lgressot@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>John Waldron</last_name>
      <phone>(832) 330-5090</phone>
      <email>JWaldron@wmrad.com</email>
    </contact_backup>
    <investigator>
      <last_name>Laurent Gressot, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Oncology, P.A. (US Oncology Research)</name>
      <address>
        <city>Round Rock</city>
        <state>Texas</state>
        <zip>78681</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zuzanne Bristow, MPH</last_name>
      <phone>281-863-4603</phone>
      <email>Zuzanne.Bristow@mckesson.co</email>
    </contact>
    <investigator>
      <last_name>Beth A. Hellerstedt, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Virginia Cancer Specialists, PC (US Oncology Research)</name>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <zip>22031</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zuzanne Bristow, MPH</last_name>
      <phone>281-863-4603</phone>
      <email>Zuzanne.Bristow@mckesson.com</email>
    </contact>
    <investigator>
      <last_name>Nicholas J. Robert, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Virginia Oncology Associates (US Oncology Research)</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23502</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zuzanne Bristow, MPH</last_name>
      <phone>281-863-4603</phone>
      <email>Zuzanne.Bristow@mckesson.com</email>
    </contact>
    <investigator>
      <last_name>Michael A. Danso, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Grand Hopital de Charleroi</name>
      <address>
        <city>Charleroi</city>
        <zip>6000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Canon Jean-Luc, MD</last_name>
      <phone>+3271104701</phone>
      <email>canon.jl@ghdc.be</email>
    </contact>
    <contact_backup>
      <last_name>Stephanie Adam</last_name>
      <phone>+3271104762</phone>
      <email>stephanie.adam@ghdc.be</email>
    </contact_backup>
    <investigator>
      <last_name>Jean-Luc Canon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
    <country>Belgium</country>
  </location_countries>
  <verification_date>June 2014</verification_date>
  <lastchanged_date>June 2, 2014</lastchanged_date>
  <firstreceived_date>September 11, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Breast cancer</keyword>
  <keyword>BRCA mutation</keyword>
  <keyword>PARP inhibitor</keyword>
  <keyword>BRCA 1</keyword>
  <keyword>BRCA 2</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
